Pharmacist Intervention in Risk Reduction Study: High-Risk Cardiac Patients
暂无分享,去创建一个
William Semchuk | R. Tsuyuki | Jeff Taylor | L. Sulz | Michelle A. Deschamps | Ross T. Tsuyuki | P. Duffy | T. W. Wilson | T. Wilson | W. Semchuk | L. Sulz | Jeff G. Taylor | M. Deschamps | P. Duffy
[1] R. Slaughter,et al. Pharmacists' Ability to Influence Outcomes of Hypertension Therapy , 1997, Pharmacotherapy.
[2] B. Irons,et al. A Retrospective Cohort Analysis of the Clinical Effectiveness of a Physician‐Pharmacist Collaborative Drug Therapy Management Diabetes Clinic , 2002, Pharmacotherapy.
[3] M. Joffres,et al. Awareness, treatment, and control of hypertension in Canada. , 1997, American journal of hypertension.
[4] R. Clifford,et al. Effect of a pharmaceutical care program on vascular risk factors in type 2 diabetes: the Fremantle Diabetes Study. , 2005, Diabetes care.
[5] R. Abbott,et al. Comparing standard care with a physician and pharmacist team approach for uncontrolled hypertension , 1998, Journal of General Internal Medicine.
[6] R. McPherson,et al. Recommendations for the Management of Dyslipidemia and the Prevention of Cardiovascular Disease: 200 , 2003 .
[7] angesichts der Corona-Pandemie,et al. UPDATE , 1973, The Lancet.
[8] S. Harris,et al. Glycemic control and morbidity in the Canadian primary care setting (results of the diabetes in Canada evaluation study). , 2005, Diabetes research and clinical practice.
[9] D. Parra,et al. Optimizing Drug Therapy in Patients with Cardiovascular Disease: The Impact of Pharmacist‐Managed Pharmacotherapy Clinics in a Primary Care Setting , 2002, Pharmacotherapy.
[10] T. Pearson,et al. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.
[11] R. Abbott,et al. The Physician and Pharmacist Team: An Effective Approach to Cholesterol Reduction , 1997, Journal of General Internal Medicine.
[12] C. Rubino,et al. Effect of a Clinical Pharmacist‐Managed Lipid Clinic on Achieving National Cholesterol Education Program Low‐Density Lipoprotein Goals , 2000, Pharmacotherapy.
[13] R. McPherson,et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[14] K. Teo,et al. A randomized trial of the effect of community pharmacist intervention on cholesterol risk management: the Study of Cardiovascular Risk Intervention by Pharmacists (SCRIP). , 2002, Archives of internal medicine.
[15] D. Gaudet,et al. Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO). , 2005, The Canadian journal of cardiology.
[16] D. Malone,et al. Clinical and economic impact of ambulatory care clinical pharmacists in management of dyslipidemia in older adults: the IMPROVE study. Impact of Managed Pharmaceutical Care on Resource Utilization and Outcomes in Veterans Affairs Medical Centers. , 2000, Pharmacotherapy.
[17] Alexander G Logan,et al. The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: part II - therapy. , 2005, The Canadian journal of cardiology.
[18] L. Jaber,et al. Evaluation of a Pharmaceutical Care Model on Diabetes Management , 1996, The Annals of pharmacotherapy.
[19] D. Malone,et al. Clinical and Economic Impact of Ambulatory Care Clinical Pharmacists in Management of Dyslipidemia in Older Adults: The IMPROVE Study , 2000 .